Pharma BD Deal Intelligence
In this Phase 1 dose-escalation and expansion study of 258 patients with mutant IDH1 relapsed or refractory acute myeloid leukemia, ivosidenib at 500 mg daily…
Agios Pharmaceuticals is selling its oncology business — including approved leukemia drug Tibsovo and an attractive pipeline of IDH-targeted candidates — to…
INDIGO Phase 3 randomized 331 patients with residual or recurrent IDH-mutant low-grade glioma to vorasidenib 40 mg or placebo. Vorasidenib produced a median…
Source summaries from our enrichment pipeline; follow links for originals.
All 15 sources with sentiment breakdown →
Servier acquired Agios Pharmaceuticals' entire oncology business for up to $2 billion ($1.8 billion upfront plus $200 million in regulatory milestones) plus royalties, gaining Tibsovo (ivosidenib), vorasidenib (brain-penetrant dual IDH1/IDH2 inhibitor), and a portfolio of IDH-mutant oncology assets.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. (this deal) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. | 2026 | $2.5B | 75 |
| Servier Pharmaceuticals LLC / Black Diamond Therapeutics, Inc. | 2025 | $780M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2020 deals · Servier Pharmaceuticals LLC deals · Oncology deals